# Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability

> **NCT07239414** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sohaib Ashraf** · enrollment: 690 (estimated)

## Conditions studied

- Cardiovascular

## Interventions

- **DRUG:** Bempedoic Acid 180 MG Oral Tablet
- **DRUG:** Rosuvastatin 5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07239414
- **Lead sponsor:** Sohaib Ashraf
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-10
- **Primary completion:** 2026-11-10
- **Final completion:** 2027-02-21
- **Target enrollment:** 690 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07239414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07239414, "Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07239414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*